Table V.

Summary of selected sparse sampling strategies for cyclosporine monitoring after Neoral^® administration

Ref	Patient group	Number of patients	AUC interval (h)	Equation	r2	%PE
[21]	HTx Stable	15	12	${\text{AUC}}_{0-12}=531+0.64\ast {\text{C}}_1+8.12\ast \text{C}4$	0.973	N/R
[215]	HTx	20 Validation: 17[215] then 14[31]	12	${\text{AUC}}_{0-12}=330.841+2.235\ast {\text{C}}_2+7.970\ast {\text{C}}_6$
	Week 1				0.951	−8.68 to +6.24
	Month 3				0.918	−7.3 to +8.58
	Year 1				0.949	−5.33 to +6.49
[6]	LTx < Week 2	12	N/R	${\text{AUC}}_{0-6}=0.496\ast {\text{C}}_2+0.517\ast {\text{C}}_3+776.9$	0.94	NR
[66]	LTx Stable	8 Validation: 6	τ, N/R	${\text{AUC}}_{0-\tau }=185.62+1.75\ast {\text{C}}_1+4.91\ast {\text{C}}_3$	0.904	−6.96 to +13.05
				${\text{AUC}}_{0-\tau }=53.54-5.47\ast {\text{C}}_0+2.11\ast {\text{C}}_1+6.44\ast {\text{C}}_3$	0.908	−10.31 to 22.43

HTx: Heart transplantation – LTx: Lung transplantation – N/R: not reported – PE: Prediction error.